As the science on vaccination and natural infection-based immunity against COVID-19 variants continues to evolve, accurately communicating study results and their limitations has never been more important.
COVID-19 has gotten a little better at infecting cells and dodging antibodies with each set of mutations in new variants. Omicron is the best at dodging antibodies, but its modified structure sacrificed virulence for antibody resistance.
LIVE April 19th, 2022 at 11:30 AM Biologics targeting coronavirus and variants of interest emerge as the latest therapeutic strategy for treating COVID-19.
After tragedy struck during a 1960s clinical trial, development of a vaccine for RSV ground to a halt. But as new RSV vaccine candidates enter late-stage clinical trials, a safe and effective vaccine is finally in sight.
Victor Torres’ talented lab members joined forces with industry partners to develop treatments and a potential vaccine for lethal Staphylococcus aureus infections.
A new vaccine targeting mosquito saliva proteins proved safe and prompted a strong immune response in humans, moving scientists one step closer to halting the transmission of all mosquito-borne pathogens.
As reports of disrupted menstrual cycles after COVID-19 vaccinations rose, researchers investigated the connection. Their reports revealed that while vaccine-associated menstrual changes may be small and temporary, knowledge of these potential side effects is vital for public trust.
Mass photometry helps researchers investigate the large and dynamic molecular assemblies that drive HIV integration and influence antiviral drug development.